Pegaptanib

Pegaptanib (Macugen) Aptamer VEGF-165 Inhibition of ligand binding AMD... [Pg.1255]

Pegaptanib 0.3 mg is administered as an intravitreous injection every 6 weeks. In clinical studies, patients treated with pegaptanib experienced a slower rate of visual decline than patients treated with a sham injection.28 Vision loss continued to occur in patients and the drug was less effective in the second year of treatment. Long-term efficacy studies are not available yet.27... [Pg.945]

Contraindications Ocular or periocular infections, hypersensitivity to pegaptanib or any component of the formulation... [Pg.943]

Parenteral 250 units/mL for IM injection Note Pegademase is bovine adenosine deaminase Pegaptanib (Macugen)... [Pg.1207]

Katz B, Goldbaum M. 2006. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF). Int Opthamol Clin. 46 141-154. [Pg.248]

Macugen (pegaptanib Aptamer Phase 3 with or without Inhibitor of vascular endothelial Age-related macular... [Pg.227]

Pegaptanib Covalently Selected vascular No rodent bioassay The safety and efficacy of Macugen beyond 2 years has... [Pg.443]

Macugen Pegaptanib sodium Eyetech Pharmaceuticals/Pfizer Marketed product Exudative AMD Intravitreal injection... [Pg.35]

These include pegaptanib sodium (Macugen) and ranibizmnab (Lucentis).These drugs are injected invitreally at specified intervals (see Chapter 31). [Pg.51]

An exploratory analysis of results from the phase III study was undertaken in patients with specifically defined early disease who received injections of 0.3 mg. Group 1 was characterized by four criteria lesion size less than two disk areas, baseline visual acuity of equal to or better than 54 EDTRS letters, no prior PDT or thermal laser photocoagulation to the lesion, and absence of scarring or atrophy within the lesion. Group 2 was characterized by three criteria occult with no classic CNV absence of lipid, and better baseline acuity in the fellow eye (or worse acuity at baseline in the study eye). Patients receiving pegaptanib treatment had response rates of... [Pg.306]

The beneficial outcomes of systemic bevacizumab therapy for CNV stimulated investigators to administer the drug intravitreally, using a dose that would be therapeutically equivalent to the systemic dose used in the SANA study but approximately 400-fold less overall (about 1.25 mg total dose vs. 5 mg/kg). Although initial studies had not suggested any benefit from bevacizumab, a 1.0-mg intravitreal injection of bevacizumab was administered to a patient with wet AMD poorly responsive to pegaptanib therapy and to another patient with macular edema after central retinal vein occlusion (CRVO). Both patients demonstrated complete resolution of edema by OCT at 1 week acuity improved from 20/200... [Pg.307]

Gonzales CR,VEGE Inhibition Smdy in Ocular Neovascularization (Vl.S.l.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium an exploratory analysis. Retina 2005 25 815. [Pg.313]

Gragoudas ES, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 2805. [Pg.313]

Siddiqui MA, Keating GM. Pegaptanib in exudative age-related macular degeneration. Drugs 2005 65 1571. [Pg.313]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...